WallStreetZenWallStreetZen

NASDAQ: SLXN
Silexion Therapeutics Corp Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their SLXN stock forecasts and price targets.

Forecast return on equity

Is SLXN forecast to generate an efficient return?

Company
-4,732.63%
Industry
257.22%
Market
146.17%
SLXN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is SLXN forecast to generate an efficient return on assets?

Company
-97.97%
Industry
109.18%
SLXN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

SLXN earnings per share forecast

What is SLXN's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$12.30-115.7%
Avg 2 year Forecast
-$7.56-109.65%
Avg 3 year Forecast
-$7.48-109.55%

SLXN revenue forecast

What is SLXN's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

SLXN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
SLXN$3.44N/AN/A
DRMA$3.70$10.00+170.27%Strong Buy
MLEC$0.62N/AN/A
ELAB$5.84N/AN/A
XRTX$0.65N/AN/A
View Top Biotech Stocks

Silexion Therapeutics Stock Forecast FAQ

What is SLXN's earnings growth forecast for 2025-2027?

(NASDAQ: SLXN) Silexion Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 26.43%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.98%.

Silexion Therapeutics's earnings in 2025 is -$15,126,000.On average, 3 Wall Street analysts forecast SLXN's earnings for 2025 to be -$9,000,075, with the lowest SLXN earnings forecast at -$8,647,130, and the highest SLXN earnings forecast at -$9,264,783. On average, 3 Wall Street analysts forecast SLXN's earnings for 2026 to be -$5,529,897, with the lowest SLXN earnings forecast at -$5,313,038, and the highest SLXN earnings forecast at -$5,692,541.

In 2027, SLXN is forecast to generate -$5,470,195 in earnings, with the lowest earnings forecast at -$5,255,677 and the highest earnings forecast at -$5,631,083.

If you're new to stock investing, here's how to buy Silexion Therapeutics stock.

What is SLXN's revenue growth forecast for 2025-2027?

(NASDAQ: SLXN) Silexion Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 108.19%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.27%.

Silexion Therapeutics's revenue in 2025 is $0.On average, 3 Wall Street analysts forecast SLXN's revenue for 2025 to be $0, with the lowest SLXN revenue forecast at $0, and the highest SLXN revenue forecast at $0. On average, 3 Wall Street analysts forecast SLXN's revenue for 2026 to be $0, with the lowest SLXN revenue forecast at $0, and the highest SLXN revenue forecast at $0.

In 2027, SLXN is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is SLXN's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: SLXN) forecast ROA is -97.97%, which is lower than the forecast US Biotechnology industry average of 109.18%.

What is SLXN's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: SLXN) Silexion Therapeutics's current Earnings Per Share (EPS) is $78.33. On average, analysts forecast that SLXN's EPS will be -$12.30 for 2025, with the lowest EPS forecast at -$11.82, and the highest EPS forecast at -$12.66. On average, analysts forecast that SLXN's EPS will be -$7.56 for 2026, with the lowest EPS forecast at -$7.26, and the highest EPS forecast at -$7.78. In 2027, SLXN's EPS is forecast to hit -$7.48 (min: -$7.18, max: -$7.70).

What is SLXN's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: SLXN) forecast ROE is -4,732.63%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.